Scribe Therapeutics Inc. Common Stock SCTX
$15.70
+1.42%
at last close
Analyst Consensus
- Consensus Rating
- Buy (4 Buy · 0 Hold · 0 Sell)
- Average Price Target
- $51.75
- Implied Upside
- +229.6%
- Price Target Range
- $37.00 – $60.00
- Analysts (12 mo)
- 4
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-09-03 | HC Wainwright & Co.Mitchell S. Kapoor |
Reiterates | Buy | $60 |
| 2026-08-31 | HC Wainwright & Co.Mitchell S. Kapoor |
Initiates coverage on | Buy | $60 |
| 2026-08-18 | Wells FargoYanan Zhu |
Initiates coverage on | Overweight | $60 |
| 2026-08-18 | Leerink PartnersDavid Risinger |
Initiates coverage on | Outperform | $37 |
| 2026-08-18 | GuggenheimDebjit Chattopadhyay |
Initiates coverage on | Buy | $50 |
Ratings and price targets reflect each firm's most recent published action. Consensus combines the latest call from every covering firm over the past 12 months; price targets are typically 12-month horizons.
Key Stats
- Last Close
- $15.70
- Market Cap
- $297.23 million
- 52-Week Range
- $13.50 – $39.60
- Average Volume
- 451K shs
Data is delayed and provided for informational purposes only. Not investment advice. See our disclaimer.